Abstract
Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Current Diabetes Reviews
Title: Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Volume: 4 Issue: 2
Author(s): Anthony Stonehouse, Ted Okerson, David Kendall and David Maggs
Affiliation:
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Abstract: Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Export Options
About this article
Cite this article as:
Stonehouse Anthony, Okerson Ted, Kendall David and Maggs David, Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors, Current Diabetes Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339908784220705
DOI https://dx.doi.org/10.2174/157339908784220705 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Intelligent Drug Delivery Systems Based on Modified Chitosan Nanoparticles
Letters in Organic Chemistry Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Fed Batch Fermentation and Purification Strategy for High Yield Production of Brucella melitensis Recombinant Omp 28 kDa Protein and its Application in Disease Diagnosis
Protein & Peptide Letters The pH of Wound Fluid in Diabetic Foot Ulcers- the Way Forward in Detecting Clinical Infection?
Current Diabetes Reviews Probiotic Properties of a Spaceflight-induced Mutant Lactobacillus Plant- arum SS18-50 in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders
Current Pharmaceutical Design From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design Regional Distribution and Kinetics of Inhaled Pharmaceuticals
Current Pharmaceutical Design Oral Solid Self-Emulsifying Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach
Current Pharmaceutical Design Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Medicinal Diets: From Molecules to Nutrients to Foods: Basic and Clinical Implications
Current Medicinal Chemistry Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery